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Abstract: The optrA gene, which confers transferable resistance to oxazolidinones and phenicols,
is defined as an ATP-binding cassette (ABC) transporter but lacks transmembrane domains.
The resistance mechanism of optrA and whether it involves antibiotic efflux or ribosomal protection
remain unclear. In this study, we determined the MIC values of all bacterial strains by broth
microdilution, and used ultra-high performance liquid chromatography-tandem quadrupole mass
spectrometry to quantitatively determine the intracellular concentrations of linezolid and florfenicol
in Enterococcus faecalis and Staphylococcus aureus. Linezolid and florfenicol both accumulated
in susceptible strains and optrA-carrying strains of E. faecalis and S. aureus. No significant
differences were observed in the patterns of drug accumulation among E. faecalis JH2-2, E. faecalis
JH2-2/pAM401, and E. faecalis JH2-2/pAM401+optrA, but also among S. aureus RN4220, S. aureus
RN4220/pAM401, and S. aureus RN4220/pAM401+optrA. ANOVA scores also suggested similar
accumulation conditions of the two target compounds in susceptible strains and optrA-carrying
strains. Based on our findings, the mechanism of optrA-mediated resistance to oxazolidinones and
phenicols obviously does not involve active efflux and the OptrA protein does not confer resistance
via efflux like other ABC transporters.
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1. Introduction
Bacteria have shown an increasing ability to resist the actions of antimicrobial agents, such
that the treatment of pathogenic bacterial infections has become a major challenge to public
health. Understanding the mechanisms of bacterial resistance is crucial for antibiotic discovery
and development. Up to now, major reported drug-resistance mechanisms include drug inactivation
by enzymes [1,2], drug efflux pumps [3,4], drug target alteration or protection [5]. Active drug efflux
pump has attracted much attention because single multidrug efflux pump can confer resistance to a
variety of drugs with different structure and function and may synergize with other drug resistance
mechanisms [6]. Active efflux pump genes have been found in Gram-positive and Gram-negative
bacteria encoded on the chromosome like norB and tet38 [7], or plasmid like msr(A) [8].
Since our first report of the plasmid-mediated optrA gene in Enterococcus faecalis and Enterococcus
faecium, which confers transferable resistance to phenicols and last-line antimicrobial oxazolidinone
drugs, in China in 2015 [9], there have been reports of the widespread dissemination of this gene
among Gram-positive bacteria [10–12]. OptrA belongs to the ATP-binding cassette (ABC) transporter
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F subfamily, which also includes the Vga, Lsa, Sal and Msr proteins, associated with multiple drug
resistance [13,14]. ABC-F proteins lack transmembrane domains, and their resistance mechanism,
whether through antibiotic efflux or ribosomal protection, remains to be clarified.
In a recent study, Sharkey et al. provided the first direct evidence that Vga and Lsa-type
proteins confer resistance by acting directly on the ribosome [15]. However, previous studies showed
that Staphylococcus aureus and Staphylococcus haemolyticus carrying msr or vga exhibited decreased
intracellular accumulation of the corresponding target antibiotics [8,16,17], although this may also
result from ribosomal protection [8]. Until now, little has been known regarding the resistance
mechanism of optrA. Knowing the mechanism of resistance, however, is important to develop new
ways to counteract optrA-mediated resistance and restore the efficacy of oxazolidinones, one of the
last-line antibiotic classes for treatment of MRSA and VRE infections in human clinical medicine.
Here, we report the use of ultra-high performance liquid chromatography-tandem quadrupole
mass spectrometry (UHPLC-MS/MS) to investigate the intracellular accumulation of linezolid
and florfenicol, as representatives of oxazolidinones and phenicols, respectively, in optrA-carrying
Enterococcus faecalis and Staphylococcus aureus. The aim of this study was to find out whether OptrA
acts as an antibiotic efflux pump.
2. Results
2.1. MIC Values
We performed antimicrobial susceptibility testing of the isolates (E. faecalis JH2-2, E. faecalis
JH2-2/pAM401, E. faecalis JH2-2/pAM401+optrA, S. aureus RN4220, S. aureus RN4220/pAM401, and S.
aureus RN4220/pAM401+optrA) and found that the MICs remained unchanged as compared to our
published data [9]. The MICs of E. faecalis JH2-2 carrying plasmid pAM401 with the cloned optrA were
64 mg/L for florfenicol and 16 mg/L for linezolid; these were 16-fold and 8-fold higher, respectively,
than the MICs of E. faecalis JH2-2 and E. faecalis JH2-2 carrying only the shuttle vector pAM401.
Similarly, the MICs of S. aureus RN4220 carrying plasmid pAM401 with the cloned optrA were 64 mg/L
for florfenicol and 8 mg/L for linezolid, while the corresponding MICs of S. aureus RN4220 and S.
aureus RN4220/pAM401 were at 4 mg/L florfenicol and 2 mg/L linezolid, respectively.
2.2. Time Course Study of Accumulation Rules
The results of the time course study of the accumulation of the target compounds are shown in
Figure 1 and Table 1. Representative UHPLC-MS/MS chromatograms of florfenicol and linezolid
in tested isolates are shown in Figure 2. For E. faecalis, the original recipient strain and the two
transformant strains exhibited similar trends in accumulation. In the low-dose groups (florfenicol,
16 mg/L; linezolid, 2 mg/L), the highest accumulation was mostly observed at 10 min, and
concentrations were slightly lower at 30 min and 60 min, while in the high-dose groups (florfenicol,
64 mg/L; linezolid, 8 mg/L), accumulation commonly peaked at 30 min and then declined again at
60 min. For S. aureus, the intracellular concentrations of compounds usually peaked at 10 min in the
high-dose florfenicol and the low-dose linezolid experiments, and at 30 min for the low-dose florfenicol
and the high-dose linezolid experiments.
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Figure 1. Accumulation of florfenicol and linezolid in the tested bacteria. (A) Florfenicol at concentration of 16 mg/L in E. faecalis. (B) Florfenicol at concentration of
64 mg/L in E. faecalis. (C) florfenicol at concentration of 16 mg/L in S. aureus. (D) Florfenicol at concentration of 64 mg/L in S. aureus. (E) Linezolid at concentration of
2 mg/L in E. faecalis. (F) Linezolid at concentration of 8 mg/L in E. faecalis. (G) Linezolid at concentration of 2 mg/L in S. aureus. (H) Linezolid at concentration of
8 mg/L in S. aureus.
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Table 1. Concentrations of florfenicol and linezolid in E. faecalis and S. aureus.






JH2-2 17.04 20.21 16.65 14.80 19.97 17.15 16.65 15.82 15.41
JH2-2 pAM401 17.77 18.48 18.93 19.73 14.85 20.40 17.67 16.75 15.73
JH2-2 optrA 19.72 19.17 18.23 17.66 18.94 17.90 14.40 15.14 17.71
64
JH2-2 51.40 52.70 49.71 51.28 55.85 60.51 52.32 58.19 52.15
JH2-2 pAM401 52.04 47.49 49.59 51.91 57.97 56.86 50.74 52.02 56.72
JH2-2 optrA 51.16 51.25 52.63 55.48 51.50 57.20 53.16 53.53 53.45
Linezolid
2
JH2-2 6.50 6.06 4.92 5.33 5.22 5.24 5.16 5.08 4.66
JH2-2 pAM401 5.07 6.09 4.97 5.76 5.45 5.60 4.91 5.11 5.17
JH2-2 optrA 5.49 5.87 5.13 5.69 5.59 4.91 5.39 4.23 5.21
8
JH2-2 18.08 18.22 18.73 17.71 17.81 17.08 7.30 7.05 7.12
JH2-2 pAM401 16.92 17.53 17.81 19.01 18.51 17.32 7.19 7.18 6.38
JH2-2 optrA 17.57 18.40 19.00 17.89 18.29 17.86 6.87 7.88 6.70
Florfenicol
16
RN4220 19.34 12.08 10.96 20.35 18.67 19.76 18.28 15.96 15.95
RN4220 pAM401 13.14 13.13 10.16 20.48 19.05 19.30 16.29 17.01 17.09
RN4220 optrA 11.77 12.92 12.60 20.72 20.43 21.77 16.56 15.79 16.18
64
RN4220 54.48 51.51 53.27 52.25 53.61 52.20 44.28 43.82 50.31
RN4220 pAM401 51.89 51.01 54.80 54.75 49.86 44.81 48.40 45.75 47.46
RN4220 optrA 53.24 57.20 55.49 47.10 48.51 49.02 44.32 42.67 45.67
Linezolid
2
RN4220 2.89 2.96 2.72 1.78 1.89 1.84 1.47 1.43 1.72
RN4220 pAM401 2.92 2.88 2.85 2.22 1.95 1.97 1.45 1.64 1.47
RN4220 optrA 2.82 2.76 2.83 1.91 1.66 2.29 1.42 1.38 1.34
8
RN4220 6.12 5.58 6.27 5.73 5.85 6.12 5.00 6.16 5.37
RN4220 pAM401 6.20 5.64 6.32 6.55 6.42 6.39 6.04 5.58 5.57
RN4220 optrA 5.55 5.72 5.87 5.92 6.31 6.84 5.08 4.97 5.26
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Figure 2. Representative UHPLC-MS/MS chromatograms of florfenicol and linezolid in tested isolates.
(A) Standard of florfenicol at concentration of 50 µg/L. (B) Standard of linezolid at concentration of
50 µg/L. (C) Florfenicol at concentration of 64 mg/L in E. faecalis JH2-2/pAM401+optrA at 60 min. (D)
Linezolid at concentration of 8 mg/L in E. faecalis JH2-2/pAM401+optrA at 60 min. (E) Florfenicol at
concentration of 64 mg/L in S. aureus RN4220/pAM401+optrA at 60 min. (F) Linezolid at concentration
of 8 mg/L in S. aureus RN4220/pAM401+optrA at 60 min.
Furthermore, analysis of variance (ANOVA) was used to analyze the significance of the
accumulation results, and comparisons were carried out between each pair of strains (Table 2).
The p-values of three comparisons, both in E. faecalis and S. aureus, were all greater than 0.05.
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10 0.692 0.337 0.554 0.424 0.491 0.905
30 0.614 0.668 0.938 0.978 0.072 0.075
60 0.474 0.836 0.365 0.928 0.449 0.401
64
10 0.288 0.774 0.193 0.739 0.189 0.117
30 0.924 0.713 0.784 0.279 0.114 0.534
60 0.647 0.715 0.924 0.606 0.363 0.177
Linezolid
2
10 0.416 0.546 0.823 0.665 0.446 0.251
30 0.166 0.567 0.370 0.261 0.515 0.604
60 0.771 0.948 0.723 0.846 0.132 0.174
8
10 0.076 0.956 0.082 0.813 0.318 0.230
30 0.160 0.340 0.591 0.060 0.106 0.697
60 0.551 0.983 0.565 0.503 0.247 0.093
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3. Discussion
According to MIC profiles, we selected for this study two incubation concentrations for each
antibiotic: 2 mg/L and 8 mg/L for linezolid and 16 mg/L and 64 mg/L for florfenicol. For the
exposure time, 10 min was chosen because it is longer than the time required to reach a steady-state
concentration, but short enough to minimize metabolic and growth changes [18]. In addition, 30-min
and 60-min time points were also included to investigate the trend in the concentrations of the two
target compounds. During the 60-min exposure time, no obvious changes were observed for the
treated strains in terms of the optical density at 600 nm (OD600).
In contrast to the use of radiolabeled antibiotics and measurement by liquid scintillation
counter [8,16,17], we lysed the cells, isolated the target compounds, and determined their
concentrations by LC-MS/MS, the “gold standard” for the identification and quantification of small
molecules [19,20]. During the sample preparation procedure, we focused on the rapid separation
of bacterial cells from culture medium and minimization of cell membrane disruption. Membrane
disruption before cell lysis disturbs the internal and external drug balance and may lead to potential
inaccuracies in the results. To address this concern, we adopted the silicone oil separation method [18],
which has been used to assess the accumulation of over 180 compounds in Escherichia coli. This method
eliminates the conventional washing step used to remove extracellular drug prior to isolating the cells
for lysis, guaranteeing the quality of the quantitative determination of intracellular drug concentrations.
In time course study of the accumulation of the target compounds, these results indicated that
no identical accumulation trend was observed in E. faecalis and S. aureus. It is worth noting that
higher dosages of both florfenicol and linezolid resulted in higher accumulation levels in all strains,
suggesting that the uptake of the drugs by the bacteria was related to the exposure concentration.
However, it was more important to evaluate the difference in accumulation between the susceptible
strains and the optrA-carrying resistant strains. No significant differences were observed in the patterns
of drug accumulation among susceptible strains and optrA-carrying resistant strains according to
the results of ANOVA. All the above mentioned results clearly demonstrated that the mechanism of
optrA-mediated resistance to oxazolidinones and phenicols obviously does not involve active efflux
and the OptrA protein does not mediate resistance via active efflux like other ABC transporters.
4. Materials and Methods
4.1. Bacterial Isolates and Growth Conditions
Linezolid- and florfenicol-susceptible and -resistant transformants of E. faecalis and S. aureus,
were obtained from our previous work [9]. They included the susceptible original E. faecalis JH2-2
and S. aureus RN4220, E. faecalis JH2-2/pAM401 and S. aureus RN4220/pAM401, which harbor the
‘empty’ shuttle vector pAM401, as well as the resistant E. faecalis JH2-2/pAM401+optrA and S. aureus
RN4220/pAM401+optrA, which harbor the same vector with a cloned and functionally active optrA
gene. The tested isolates were grown in brain heart infusion broth and incubated at 37 ◦C with
200 rpm shaking.
4.2. Antimicrobial Susceptibility Testing
The MICs of all susceptible and resistant strains were determined by broth microdilution following
the recommendations given in the Clinical and Laboratory Standards Institute (CLSI) documents
VET01-S3 and M100-S25 [21,22].
4.3. Accumulation and Extraction
Intracellular accumulation assays were performed as described previously with slight
modifications [18]. Specifically, 3 mL of overnight cultures of S. aureus or E. faecalis was added
to 300 mL fresh brain heart infusion broth (Beijing Land Bridge Technology Co., Ltd., Beijing, China)
and incubated at 37 ◦C with shaking at 200 rpm until the bacterial growth reached the mid-log phase
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(OD600 = 0.4). Bacterial cells were harvested at 3200× g for 10 min at 4 ◦C, and the supernatant
was discarded. Cell pellets were re-suspended in 40 mL of fresh phosphate-buffered saline (PBS),
followed by centrifugation as before and removal of the supernatant. The resulting cell pellets were
re-suspended in 6.6 mL PBS, and 650 µL of each cell solution was transferred into a 1.5-mL Eppendorf
tube. After equilibrating at 37 ◦C with shaking for 5 min, the target compounds were added: florfenicol
at final concentrations of 16 or 64 mg/L and linezolid at final concentrations of 2 or 8 mg/L. Triplicate
samples were prepared for each concentration. Samples were incubated at 37 ◦C with shaking for
10, 30, and 60 min. After incubation, 600 µL of each culture was carefully transferred into 700-µL
precooled (−78 ◦C) silicone oil (AR20/Sigma High Temperature 9:1, v/v) to separate the bacterial cells
from solution without disturbing the intracellular and extracellular drug equilibrium. Samples with
oil were centrifuged at 20,000× g for 3 min, and the supernatant and oil were discarded.
For sample lysis, each cell pellet was resuspended in 300 µL water-methanol (2:1, v/v), and
a freeze-thaw cycle of 3 min in liquid nitrogen followed by 3 min in a water bath at 65 ◦C was
performed three times. Lysates were centrifuged at 20,000× g for 5 min at room temperature, and the
supernatants were transferred into new Eppendorf tubes and centrifuged at 20,000× g for 20 min at
4 ◦C. The supernatant was diluted 100-fold with water-methanol (2:1, v/v) and vortex-mixed prior to
LC-MS/MS analysis.
4.4. LC-MS/MS Analysis
Samples were analyzed by a Waters Acquity ultra-performance liquid chromatography system
coupled to a Micromass Xevo TQ-S triple quadrupole mass spectrometer (Waters, Manchester, UK)
fitted with an electrospray ionization (ESI) source. LC separation was performed using an Acquity
BEH C18 column (50 mm × 2.1 mm i.d., 1.7 µm particle size; Waters) maintained at 40 ◦C. The mobile
phase was constituted by solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in
acetonitrile) for linezolid, and solvent A (water) and solvent B (acetonitrile) for florfenicol. The flow
rate was 0.4 mL/min with a linear gradient under the following conditions: 0–0.2 min, 95% A; 0.2–2.0
min, 95–50% A; 2.0–2.1 min, 50–5% A; 2.1–2.5 min, 5% A; 2.5–2.6 min, 5–95% A; 2.6–4.0 min, 95% A.
The injection volume was 5 µL.
The source conditions of the MS/MS system were as follows: capillary voltage, 2.5 kV; source
temperature, 150 ◦C; desolvation temperature, 500 ◦C; cone gas (N2) flow rate, 50 L/h; desolvation gas
(N2) flow rate, 800 L/h. Linezolid was analyzed in positive ESI mode, while florfenicol was detected
in negative ESI mode. Data were acquired in multiple reaction monitoring mode using MassLynx
software v4.1 with the QuanLynx program (Waters, Milford, MA, USA). Optimized MS/MS transitions
as well as specific cone voltages and collision energies were as follows: linezolid, cone voltage 30 V,
m/z 338.2 > 296.0 (collision energy 18 eV, transition for quantification), m/z 338.2 > 195.2 (collision
energy 22 eV); florfenicol, cone voltage 48 V, m/z 355.9 > 336.0 (collision energy 8 eV, transition for
quantification), m/z 355.9 > 184.9 (collision energy, 22 eV). Auto dwell time was applied to ensure that
approximately 15 data points were acquired for each chromatographic peak.
4.5. Statistical Analysis
Differences in the intracellular drug concentrations were analyzed by SPSS Statistics 21 (IBM
Corporation, Armonk, NY, USA), and statistical significance was determined by one-way ANOVA
with 95% confidence intervals.
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